As forward-looking research as well as a leading custom service provider in the field of drug discovery, Creative Biolabs is always pleased to use our extensive experience and advanced platform to offer one-stop anti-monkeypox drug discovery solutions to satisfy each demand from our customers.
As the leading custom service provider, Creative Biolabs has been keeping a close eye on the development of the epidemic situation and accelerating the development of detection kits. Creative Biolabs provides Monkeypox virus nucleic acid detection kits and ELISA kits.
Creative Biolabs is the leading custom service provider that has extensive experience in various antibody production and engineering fields. As the leading custom service provider specializing in antibody production and engineering fields, Creative Biolabs has been keeping a close eye on the development of the epidemic situation and accelerating the development of monkeypox antibodies.
With years of experience, Creative Biolabs can offer an extensive range of recombinant proteins and peptides including orthopoxviruses family, parapoxviruses family, molluscipoxviruses family, yatapoxviruses family, capripoxviruses family, suipoxviruses family, leporipoxviruses family and avipoxviruses family. Creative Biolabs is committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Creative Biolabs has organized a staff of outstanding scientists who have engaged in the research of macrophage reprogramming for many years. Our seasoned scientists have developed several efficient strategies for macrophage reprogramming, including Reprogramming Macrophages Employing Gene Regulatory Networks, Reprogramming Macrophages By Nanoparticles, and Reprogramming Macrophages by microRNA.
As a leading service provider in the field of antibody discovery and immunotherapy development, Creative Biolabs now presents one-stop development services for CAR-T therapy, which has become a more promising approach among cancer therapies. We offer macrophage polarization assay used to improve the antitumor immunity via promoting inflammation during the one-stop service for further downstream research.
Lipid nanoparticles (LNPs) are novel spherical vesicles with core-shell nanostructure. A typical LNP usually has a specially designed ionizable lipid component, which is positively charged at low pH (for RNA complexation) and neutral at physiological pH (reducing potential toxic effects compared with cationic liposomes). Due to their special characteristics and small size (~100 nm), LNPs could be uptake by cells via endocytosis and then release the cargo into the cytoplasm by low pH mediated endosomal escape. Thus, the LNPs possess additional advantages over the traditional lipid-based carriers such as improved nucleic acid encapsulation and transfection efficiency, better penetration capacity, and decreased cytotoxicity.
Creative Biolabs has more than ten years of experience in developing liposomal formulations. We integrate the knowledge of well-known liposome academics into our liposome technology. Our team of liposome experts and support staff has successfully served thousands of customers all over the world. At Creative Biolabs, we provide a full set of liposomes custom services, we also offer various liposome analysis services to characterize liposome-based product and measure the embedding efficiency. We believe our best liposome products and services will meet the highest standards.
Introduction of Fatty Acids (FAs) are carboxylic acids with a long aliphatic chain, either saturated or unsaturated. FA vesicles are colloidal suspensions of closed lipid bilayers, which are composed of fatty acids and their ionized species (soap). They are observed in a small region within the fatty acid-soap-water ternary phase diagram above the chain melting temperature (Tm) of the corresponding fatty acid-soap mixture.
Introduction to iPSC Research Methods: The iPSC technology is undoubtedly the most outstanding achievement made by the Stem Cell Research Institute, so it was selected as the top scientific and technological breakthrough in 2009. Unlike classic embryonic stem cell technology and somatic cell nuclear transfer technology, iPSC technology does not use embryonic cells or egg cells, avoiding ethical disputes. Moreover, the patient can use iPSC derived from autologous cells, thus avoiding immune rejection. In all, iPSC technology is greatly promising for clinical cell therapy.